Steroid News and Research

RSS

Anti-aging supplement: A fountain of hope for would-be mothers

According to the American Pregnancy Association, six million women a year deal with infertility. Now, a Tel Aviv University study is giving new hope to women who want to conceive ― in the form of a pill they can find on their drugstore shelves right now.

2 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Today, the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) announced the release of a consensus statement to address ambiguities and disparities in the diagnosis and management of nasal valve compromise (NVC).

1 Jul 2010

Individual variants of environmental toxins can affect body's hormone systems: Research

Marianne Kraugerud's doctoral research has led to the discovery that individual variants of the environmental pollutants PCB and PFC can affect several of the body's hormone systems in a more complex way than previously supposed. Humans and animals are constantly exposed to these toxins through the food they eat and the air they breathe. Kraugerud concludes that the impact of these pollutants should be taken into account when carrying out risk appraisals of PCB and PFC.

1 Jul 2010

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

29 Jun 2010

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

29 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Oral micronized progesterone effective for women with symptomatic hot flashes

Postmenopausal women who experience bothersome hot flashes or night sweats may have an alternative treatment to estrogen. According to a new study, oral micronized progesterone relieves those symptoms. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

BIOTRONIK SE & Co. KG, a leading manufacturer of high-quality implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the commercial availability of its new ProMRI Pacing Systems — Evia pacemaker series and Safio pacing leads — providing European patients the first portfolio of bradycardia systems that are compatible with Magnetic Resonance Imaging scans under specific conditions.

15 Jun 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Otonomy completes $10 million Series A financing with Avalon Ventures

Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Meniere's disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.

11 Jun 2010

Harbor BioSciences closes $2.06M common stock registered direct offering

Harbor BioSciences, Inc. announced today that it has closed its previously announced sale of approximately $2.06 million of its common stock and warrants in a registered direct offering, issuance and sale to select investors.

11 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Steroid News and Research

Anti-aging supplement: A fountain of hope for would-be mothers

New asthma therapy shows promise for patients who do not respond to steroid treatments

AAO-HNS releases CCS to address ambiguities, disparities in diagnosis and management of nasal valve compromise

Individual variants of environmental toxins can affect body's hormone systems: Research

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

pSivida's licensee submits NDA to FDA for Iluvien

Vitae earns $14M milestone payment from Boehringer Ingelheim

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Oral micronized progesterone effective for women with symptomatic hot flashes

Women with PCOS may be more vulnerable to BPA exposure: Study

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

FDA approves Jevtana to treat men with prostate cancer

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Otonomy completes $10 million Series A financing with Avalon Ventures

Harbor BioSciences closes $2.06M common stock registered direct offering

Some commonly used drugs cause bone loss: New research

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News